Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083

By sjmartinez • November 24, 2024

Clement ME, Hanscom B, Haines D, Bazan JA, Chotirosniramit N, Kofron R, Mannheimer S, Mayer KH, Torres Silva MS, Soto-Torres L, Rinehart AR, Rooney JF, Jennings A, Gomez-Feliciano K, McCauley M, Grinsztejn B, Landovitz RJ; for HPTN 083 Study Team. Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083. Clin Infect Dis. 2024 Nov 23:ciae572. doi: 10.1093/cid/ciae572. Epub ahead of print. PMID: 39579334.

Tags: bacterial sexually transmitted infections, CAB-LA, efficacy, HIV prevention, Infectious Diseases, Long-acting PrEP, Publications

Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment

Munroe ES, Grandits GA, Hyzy RC, Prescott HC, Barrett TW, Dewar RL, Engen N, Goodman AL, Hatlen TJ, Highbarger H, Holland TL, Hughes G, Jensen[...]

Three Cases of Vertical Transmission of Clade Ib Mpox Virus

Vakaniaki EH, Kuispond NS, Hirata Y, Bangwen E, Brosius I, Kinganda-Lusamaki E, Ozono S, Katano H, Ndunge LG, Mulopo-Mukanya N, Tshomba JC, De Vos E,[...]

Pearls and Pitfalls of Intrathecal Amphotericin B Therapy for Refractory Coccidioidal Meningitis in Children: An Illustrative Pediatric Case Series

Malhotra S, Adachi K, Fallah A, Johnson R, Ishminder Kaur, McCarty J, Ross L, Krogstad P. Pearls and Pitfalls of Intrathecal Amphotericin B Therapy for[...]